| European Case Law Identifier: | ECLI:EP:BA:2016:T225512.20160531 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 31 May 2016 | ||||||||
| Case number: | T 2255/12 | ||||||||
| Application number: | 06778240.9 | ||||||||
| IPC class: | A61K 9/36 A61K 38/46 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | D | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Controlled release pharmaceutical compositions for acid labile drugs | ||||||||
| Applicant name: | Abbott Laboratories GmbH | ||||||||
| Opponent name: | Aptalis Pharma S.r.l. | ||||||||
| Board: | 3.3.07 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Amendments - allowable (yes) Inventive step - (yes) |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t122255eu1.html
Date retrieved: 17 May 2021